Search Results - "Teo, Hsiang Ling"
-
1
Hexamethylene Bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF-κB activity: Implications for cancer therapy
Published in Cell cycle (Georgetown, Tex.) (01-12-2008)“…Hexamethylene Bisacetamide (HMBA) is a hybrid polar compound originally developed as a differentiation inducing agent. We show in this study that HMBA can…”
Get full text
Journal Article -
2
An efficient proteome-wide strategy for discovery and characterization of cellular nucleotide-protein interactions
Published in PloS one (06-12-2018)“…Metabolite-protein interactions define the output of metabolic pathways and regulate many cellular processes. Although diseases are often characterized by…”
Get full text
Journal Article -
3
The human telomeric nucleosome displays distinct structural and dynamic properties
Published in Nucleic acids research (04-06-2020)“…Telomeres protect the ends of our chromosomes and are key to maintaining genomic integrity during cell division and differentiation. However, our knowledge of…”
Get full text
Journal Article -
4
Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays
Published in Scientific reports (10-07-2015)“…Previous publications on stapled peptide inhibitors against Mdm2/Mdm4-p53 interactions have established that this new class of drugs have the potential to be…”
Get full text
Journal Article -
5
The structure and catalytic mechanism of human sphingomyelin phosphodiesterase like 3a – an acid sphingomyelinase homologue with a novel nucleotide hydrolase activity
Published in The FEBS journal (01-03-2016)“…Human sphingomyelinase phosphodiesterase like 3a (SMPDL3a) is a secreted enzyme that shares a conserved catalytic domain with human acid sphingomyelinase…”
Get full text
Journal Article -
6
Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy
Published in Cell cycle (Georgetown, Tex.) (01-12-2008)“…Hexamethylene Bisacetamide (HMBA) is a hybrid polar compound originally developed as a differentiation inducing agent. We show in this study that HMBA can…”
Get full text
Journal Article